PharmAsia News

We've Moved

PharmAsia News has moved to a new enhanced Web platform.  For continued news and analysis related to Asia, please visit our new site at www.pharmasianews.com and sign up for a 30-day free trial.

Semiweekly Roundup: Jan. 3, 2008

• When MNC Drug Patents Expire, Firms Turn To Making Developing-Nation Drugs (India)
• NGOs Fault Most Indian Drug Makers For Corporate Social Responsibility Efforts (India)
• Indian Pharmas Now Dominate Country’s Market In Wake Of Patent Reforms (India)
• Leavitt Plans India Visit To Discuss Safe Pharmaceutical Exports (India)
• Pfizer Japan To Ban 5,000 Workers From Smoking On The Job (Japan)
• Taiwan Researchers Find Cancer-Fighting Ingredients In Local Weeds (Taiwan)
• Australian PBS Adds Asbestos, Smoking-Cessation Drugs To Coverage (Australia)
• Vietnam Research Leads To Cancer Drug In Abundant Local Plant (Vietnam)
• Drug Experts Concerned About Increased Chinese-Drug Exports To U.S., Europe (China)
• Plaintiffs Accept Draft Bill To Settle Hepatitis C Suits (Japan)
• Japanese Inspection Finds More Tainted Blood Products (Japan)
• U.S. FDA Warns Of Chinese Supplements Containing Viagra (China)
• Japan’s Eisai Says It Still Has Patent Protection For Aricept Despite Court Action (Japan)
• Indian Pharmas Look To Herbal Medicines As Huge Potential (India)

Medivir Transfers HIV Drug Alovudine License To Beijing Mefuvir

SHANGHAI – Sweden-based Medivir AB will transfer its license and intellectual property for its HIV drug Alovudine (MIV-310) to subsidiary Beijing Mefuvir, Medivir announced Dec. 21.

MPI Research And Shanghai Medicilon Form Shanghai-Based Joint Venture

SHANGHAI – Michigan-based MPI Research has entered into a joint venture with Shanghai Medicilon to establish a preclinical research center in Shanghai that meets U.S. FDA and other international regulatory standards, the companies announced Dec 19.